A Study of LY3039478 in Participants With Advanced Cancer

Inclusion Criteria:

• For all parts: The participant must be, in the judgment of the investigator, an appropriate candidate for experimental therapy after available standard therapies have failed to provide clinical benefit for their advanced or metastatic cancer.
• For Dose Escalation (Part A): The participant must have histological or cytological evidence of cancer, either a solid tumor or a lymphoma, which is advanced or metastatic.
• For Dose Confirmation (Part B): All participants must have a histological evidence of their advanced or metastatic cancer and prescreened alterations in a defined pathway such as mutations, amplification or gene expressions related to the defined pathway.

• As defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1), the Revised Response Criteria for Malignant Lymphoma or the Response Assessment in Neuro Oncology (RANO) criteria for glioblastoma:

  • For Dose Escalation (Part A): Have measurable or nonmeasurable disease.
  • For Dose Confirmation (Parts B): Have measurable disease or reliable biomarker measure (example prostate-specific antigen [PSA], cancer antigen 125 [CA125]).

• Have adequate organ function including:

  • Hematologic: Absolute neutrophil count (ANC) at least 1.5 x 109/Liter (L), platelets at least 100 x 109/L, and hemoglobin at least 8 grams per deciliter (g/dL). Participants may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator; however, initial study drug treatment must not begin earlier than the day after the erythrocyte transfusion.
  • Hepatic: Bilirubin no more than 1.5 times upper limits of normal (ULN) and alanine aminotransferase (ALT) no more than 2.5 times ULN. If the liver has tumor involvement, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) equaling 5 times ULN are acceptable.
  • Renal: calculated creatinine clearance at least 45 milliliters per minute (mL/min)
• Have a performance status of less than or equal to 1 on the Eastern Cooperative Oncology Group (ECOG) scale and life expectancy of more than 12 weeks.
• Have discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and investigational therapy) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug, and recovered from the acute effects of therapy (treatment-related toxicity resolved to baseline) except for residual alopecia. At the discretion of the investigator, participants with breast or prostate cancers progressing on therapies may have that treatment continued while receiving study drug.

Exclusion Criteria:

• Have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agent, respectively.
• Have serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study (for example, inflammatory bowel disease or history of major surgical resection involving the stomach or small bowel).

• Have central nervous system (CNS) malignancy, except:

  • Participants with treated CNS metastases are eligible for this study if they are not currently receiving corticosteroids and/or anticonvulsants, and their disease is asymptomatic and radiographically stable for at least 60 days (screening not required).
  • Participants with glioblastoma are eligible.
• Have an acute leukemia.
• Have received an autologous or allogeneic stem-cell transplant.
• Females who are pregnant or lactating.
• Have active bacterial, fungal, and/or known viral infection (for example, human immunodeficiency virus [HIV] antibodies, hepatitis B surface antigen [HBSAg], or hepatitis C antibodies). Screening is not required for enrollment.
• Have malabsorptive syndromes, enteropathies, gastroenteritis (acute or chronic), or diarrhea (acute or chronic).